A phase II study of the gamma secretase inhibitor RO4929097 in patients with previously treated metastatic pancreatic adenocarcinoma
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A phase II study of the gamma secretase inhibitor RO4929097 in patients with previously treated metastatic pancreatic adenocarcinoma
Authors
Keywords
Pancreatic cancer, Notch signaling, Gamma secretase inhibitor, Pharmacokinetics
Journal
INVESTIGATIONAL NEW DRUGS
Volume 32, Issue 4, Pages 739-745
Publisher
Springer Nature
Online
2014-03-26
DOI
10.1007/s10637-014-0083-8
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A phase I study of the combination of ro4929097 and cediranib in patients with advanced solid tumours (PJC-004/NCI 8503)
- (2013) S Sahebjam et al. BRITISH JOURNAL OF CANCER
- A phase Ib combination study of RO4929097, a gamma-secretase inhibitor, and temsirolimus in patients with advanced solid tumors
- (2013) Ivan Diaz-Padilla et al. INVESTIGATIONAL NEW DRUGS
- A phase I study of the oral gamma secretase inhibitor R04929097 in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575)
- (2013) Suzanne Richter et al. INVESTIGATIONAL NEW DRUGS
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
- (2013) Daniel D. Von Hoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- A phase II study of RO4929097 in metastatic colorectal cancer
- (2012) Jonathan R. Strosberg et al. EUROPEAN JOURNAL OF CANCER
- Phase I Study of RO4929097, a Gamma Secretase Inhibitor of Notch Signaling, in Patients With Refractory Metastatic or Locally Advanced Solid Tumors
- (2012) Anthony W. Tolcher et al. JOURNAL OF CLINICAL ONCOLOGY
- Notch and Kras in pancreatic cancer: At the crossroads of mutation, differentiation and signaling
- (2011) Jean-Paul De La O et al. CELL CYCLE
- Validation and implementation of a liquid chromatography/tandem mass spectrometry assay for quantitation of the total and unbound RO4929097, a γ-secretase inhibitor targeting Notch signaling, in human plasma
- (2011) Jianmei Wu et al. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
- (2011) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
- TW-37, a Small-Molecule Inhibitor of Bcl-2, Inhibits Cell Growth and Induces Apoptosis in Pancreatic Cancer: Involvement of Notch-1 Signaling Pathway
- (2009) Z. Wang et al. CANCER RESEARCH
- Acquisition of Epithelial-Mesenchymal Transition Phenotype of Gemcitabine-Resistant Pancreatic Cancer Cells Is Linked with Activation of the Notch Signaling Pathway
- (2009) Z. Wang et al. CANCER RESEARCH
- Ligand-dependent Notch Signaling Is Involved in Tumor Initiation and Tumor Maintenance in Pancreatic Cancer
- (2009) M. E. Mullendore et al. CLINICAL CANCER RESEARCH
- Inhibition of γ-Secretase Activity Inhibits Tumor Progression in a Mouse Model of Pancreatic Ductal Adenocarcinoma
- (2009) Ruben Plentz et al. GASTROENTEROLOGY
- Essential role of Notch signaling in apoptosis of human pancreatic tumoral cells mediated by exosomal nanoparticles
- (2009) Elodie Ristorcelli et al. INTERNATIONAL JOURNAL OF CANCER
- Developmental biology of the pancreas: A comprehensive review
- (2008) George K. Gittes DEVELOPMENTAL BIOLOGY
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now